Document Actions
Documents and Special Reports
Reports and other documents of interest to readers.
- The Potti Scandal documents mentioned in The Cancer Letter, July 30, 2010: Potti's bio submitted to Department of Defense.
- The Potti Scandal documents mentioned in The Cancer Letter, July 23, 2010: Letter by 33 biostatisticians to NCI Director Harold Varmus. Letter by American Cancer Society Chief Medical Officer Otis Brawley to Duke University. A list of Potti's technologies available for licensing from Duke. More detailed description of one of these technologies.
- Duke scientist Anil Potti's different CVs: version 1, version 2, and version 3. His University of North Dakota Residency application, and a page from a Duke brochure listing his claimed Rhodes scholarship.
- City of Hope dispute with for-profit physician group reading materials (.zip file), referenced in The Cancer Letter, May 28, 2010.
- Entertainment Industry Foundation's 2008 IRS Form 900, referenced in The Cancer Letter, May 21, 2010.
- Documents on Duke University genomics research: Duke report and email obtained by The Cancer Letter; comments by biostatisticians on the report (The Cancer Letter, May 14, 2010).
- Letters by American Society of Clinical Oncology and the Massachusetts Hospital Association protesting Mass. Blues restrictions on ESAs (The Cancer Letter, April 9. 2010).
- Analysis of industry-sponsored phase I studies prepared by The Cancer Letter for article in March 26, 2010, issue.
- NCI concept statements: Barrett's Esophagus Translational Research Network and Commercial Application and Use of Emerging Molecular Analysis Technologies (SBIR) (The Cancer Letter, March 19, 2010).
- NCI concept statement: Clinical Proteomic Technologies for Cancer (The Cancer Letter, March 12, 2010).
- Documents (zip file) in Allergan lawsuit against FDA over off-label use promotion (The Cancer Letter, Jan. 15, 2010).
- State Attorneys General and whistleblower suit against Amgen on overfill of Aranesp vials, referenced in The Cancer Letter, Nov. 6, 2009.
- GAO report on New Drug Approval, referenced in The Cancer Letter, Oct. 30, 2009.
- Table summarizing data supplied to Duke investigators in connection with Dec. 2007 paper in The Lancet Oncology (referenced in The Cancer Letter, Oct. 23, 2009).
- AMA advisory committee comments on CMS 2008 physician fee schedule (referenced in The Cancer Letter, July 10, 2009).
- Sentencing hearing transcript of former Bristol-Myers Squibb executive Andrew Bodnar (referenced in The Cancer Letter, June 12, 2009).
- Stand Up to Cancer Q&A talking points (referenced in The Cancer Letter, May 29, 2009).
- Leslie Bernstein letter to Sen. Amy Klobuchar on the EARLY Act (quoted in TCL April 10, 2009).
- National Breast Cancer Coalition's analysis of the EARLY Act (mentioned in TCL April 10, 2009).
- NIH Acting Director Raynard Kington remarks Feb. 18, 2009, on plans for spending $10.4 billion economic stimulus funds, and question-and-answer session. (Two separate audio files).
- Letter from the Accreditation Council for Continuing Medical Education regarding sanctioning of the Massachusetts Medical Society on I-ELCAP study. Notice of Correction Action by MMS.
- Meeting materials from Early Analysis of Lung Screening Data meeting Sept. 22-23, 2008.
- Cell Phone studies in a table compiled by ACS staff.
- Ortho vs. Amgen: Complaint
- Ortho vs. Amgen: Defendant's Memorandum
- FDA Oncology Drug Approvals from 2005-2008 (PowerPoint presentation).
- Transcript of NCI Board of Scientific Advisors discussion of ESA and Tumor Growth RFA concept.
- NCI RFA Concept on ESAs and Tumor Growth as presented to BSA on June 23, 2008.
- Report from NCI workshop on ESAs and Tumor Growth, Dec. 2007.
- NIH response to Dingell-Stupak letter on alleged conflicts in NLST.
- Sen. Grassley letter on conflicts in NIH extramural program, June 4, 2008.
- FDA's Professional Needs Budget sent to Sen. Arlen Specter May 5, 2008.
- FDA documents on Procrit direct-to-consumer advertising compiled by the Subcommittee on Oversight and Investigations of the House Committee on Energy & Commerce for a May 8, 2008, hearing.
- NSABP Response to NIH Rejection of P-4 Appeal.
- NIH Rejection of NSABP Appeal on P-4 Trial Cancellation.
- NSABP memo of March 26, 2008, on changes to informed consent policies.
- Indictment of Andrew Bodnar, former Bristol-Myers Squibb executive.
- Claudia Henschke's disclosure letter to American Cancer Society, Feb. 7, 2008.
- The NCI 2015 Goal (Special Report, August 2003)
- The National Dialogue on Cancer 2000-2002 (Special Report, August 2003)
- ImClone: The C225 Controversy (Special Report, March 2002)
Forgot your password?